Condition: Ovarian Cancer · Sponsor: The Affiliated Hospital of Xuzhou Medical University
This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T cells (fhB7H3.CAR-Ts) via using a '3+3+3' dose escalation design. In the dose expansion cohort, six patients will be enrolled to further assess their efficacy with the optimal dosage.
This description comes directly from the study's public registry record.
Liantao Li, M.D., Ph.D. · +86-516-85582530 · liliantao@xzhmu.edu.cn
Xin Ding, M.D., Ph.D. · +86-516-83355832 · dingxin81@163.com
Always discuss trial participation with your own doctor first.
| The Affiliated Hospital of Xuzhou Medical University | Xuzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05211557